Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glasdegib for Sclerotic Chronic Graft-Vs-Host Disease
NCT04111497Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2019
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of glasdegib in chronic graft-versus-host disease (cGVHD), sponsored by Fred Hutchinson Cancer Center. Started Dec 2019; status: terminated.
02
Drugs
glasdegib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT04111497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04111497.